Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000;2000(2):CD001545.
doi: 10.1002/14651858.CD001545.

Palliative chemotherapy for advanced or metastatic colorectal cancer. Colorectal Meta-analysis Collaboration

Lesley Best  1 , Peter Simmonds  1 , Chris Baughan  2 , Roger Buchanan  3 , Carol Davis  4 , Ian Fentiman  5 , Steve George  6 , Margot Gosney  7 , John Northover  8 , Chris Williams  9 ; Collaboration Colorectal Meta‐analysis  10
Affiliations

Palliative chemotherapy for advanced or metastatic colorectal cancer. Colorectal Meta-analysis Collaboration

Lesley Best et al. Cochrane Database Syst Rev. 2000.

Abstract

Background: Despite the increasing use of palliative chemotherapy for advanced colorectal cancer, there remains uncertainty as to the true effectiveness of this intervention. This review was therefore undertaken to assess the available evidence for the benefit of palliative chemotherapy in this disease.

Objectives: To determine the benefits and harms of palliative chemotherapy in patients with locally advanced or metastatic colorectal cancer. A secondary objective was to investigate outcomes for younger and elderly patients.

Search strategy: Trials were identified by computerised and hand searches of the literature, scanning references and contacting investigators.

Selection criteria: All randomised controlled trials of palliative chemotherapy compared with supportive care alone in patients with advanced or metastatic colorectal cancer. Both randomised and non-randomised studies were considered when searching for data on quality of life, resource use and cost effectiveness of palliative chemotherapy.

Data collection and analysis: Investigators from all eligible studies were asked to supply individual patient data. Meta-analysis was performed using both published data and individual patient data. Studies were grouped according to whether chemotherapy was administered regionally or systemically.

Main results: 13 randomised controlled trials representing a total of 1365 randomised patients met the inclusion criteria. Meta-analysis of a subset of trials that provided individual patient data demonstrated that palliative chemotherapy was associated with a 35% (95% CI 24% to 44%) reduction in the risk of death. This translates into an absolute improvement in survival of 16% at both 6 months and 12 months and an improvement in median survival of 3.7 months. The overall quality of evidence relating to treatment toxicity, symptom control and quality of life was poor.

Reviewer's conclusions: Chemotherapy is effective in prolonging time to disease progression and survival in patients with advanced colorectal cancer. The survival benefit may be underestimated by this meta-analysis, as a proportion of patients in the control arms of some trials received chemotherapy. No age related differences were found in the effectiveness of chemotherapy, but elderly patients were under represented in trials. Treatment toxicity and impact upon quality of life and symptom control have been inadequately assessed in the majority of trials and further research is needed to clarify the palliative benefit of chemotherapy.

PubMed Disclaimer

Conflict of interest statement

None

Figures

1.1
1.1. Analysis
Comparison 1 Palliative chemotherapy versus supportive care and/or delayed chemotherapy, Outcome 1 Death within 6 months.
1.2
1.2. Analysis
Comparison 1 Palliative chemotherapy versus supportive care and/or delayed chemotherapy, Outcome 2 Death within 6 months (Sensitivity analysis A).
1.3
1.3. Analysis
Comparison 1 Palliative chemotherapy versus supportive care and/or delayed chemotherapy, Outcome 3 Death within 6 months (Sensitivity analysis B).
1.4
1.4. Analysis
Comparison 1 Palliative chemotherapy versus supportive care and/or delayed chemotherapy, Outcome 4 Death within 12 months.
1.5
1.5. Analysis
Comparison 1 Palliative chemotherapy versus supportive care and/or delayed chemotherapy, Outcome 5 Death within 12 months (Sensitivity analysis A).
1.6
1.6. Analysis
Comparison 1 Palliative chemotherapy versus supportive care and/or delayed chemotherapy, Outcome 6 Death within 12 months (Sensitivity analysis B).
1.7
1.7. Analysis
Comparison 1 Palliative chemotherapy versus supportive care and/or delayed chemotherapy, Outcome 7 Death within 18 months.
1.8
1.8. Analysis
Comparison 1 Palliative chemotherapy versus supportive care and/or delayed chemotherapy, Outcome 8 Death within 18 months (Sensitivity analysis B).
1.9
1.9. Analysis
Comparison 1 Palliative chemotherapy versus supportive care and/or delayed chemotherapy, Outcome 9 Death within 24 months.
1.10
1.10. Analysis
Comparison 1 Palliative chemotherapy versus supportive care and/or delayed chemotherapy, Outcome 10 Death within 24 months (Sensitivity analysis B).
1.11
1.11. Analysis
Comparison 1 Palliative chemotherapy versus supportive care and/or delayed chemotherapy, Outcome 11 Progression at 3 months.
1.12
1.12. Analysis
Comparison 1 Palliative chemotherapy versus supportive care and/or delayed chemotherapy, Outcome 12 Progression at 6 months.
1.13
1.13. Analysis
Comparison 1 Palliative chemotherapy versus supportive care and/or delayed chemotherapy, Outcome 13 Progression at 9 months.
1.14
1.14. Analysis
Comparison 1 Palliative chemotherapy versus supportive care and/or delayed chemotherapy, Outcome 14 Progression at 12 months.
2.1
2.1. Analysis
Comparison 2 Palliative chemotherapy versus supportive care and/or delayed chemotherapy (Individual Patient Data), Outcome 1 Death.
2.2
2.2. Analysis
Comparison 2 Palliative chemotherapy versus supportive care and/or delayed chemotherapy (Individual Patient Data), Outcome 2 Death (sensitivity analysis).
2.3
2.3. Analysis
Comparison 2 Palliative chemotherapy versus supportive care and/or delayed chemotherapy (Individual Patient Data), Outcome 3 Progression.
2.4
2.4. Analysis
Comparison 2 Palliative chemotherapy versus supportive care and/or delayed chemotherapy (Individual Patient Data), Outcome 4 Death by agegroup.
2.5
2.5. Analysis
Comparison 2 Palliative chemotherapy versus supportive care and/or delayed chemotherapy (Individual Patient Data), Outcome 5 Progression by agegroup.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Allen Mersh {published and unpublished data}
    1. Allen Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepatic‐artery floxuridine infusion for colorectal liver metastases. Lancet 1994;344(8932):1255‐60. - PubMed
    1. Earlam S, Glover C, Davies M, Fordy C, Allen Mersh TG. Effect of regional and systemic fluorinated pyrimidine chemotherapy on quality of life in colorectal liver metastasis patients. J‐Clin‐Oncol 1997;15(5):2022‐9. - PubMed
Beretta {published data only}
    1. Beretta G, Bollina R, Cozzi C, Morabito A. Should we consider the weekly chemotherapy with fluorouracil + racemic folic acid a standard treatment for advanced / metastatic carcinoma of the digestive tract in elderly patients?. Proceedings ASCO 1997;16:A920.
    1. Beretta G, Bollina R, Labianca R, et al. A controlled trial of supportive care (SC) versus supportive care plus 5‐fluorouracil/folinic acid for advanced metastatic gastrointestinal carcinomas in elderly patients. Proceedings ASCO 1994;113:A669.
Chisholm {published data only}
    1. Chishom E, Malhotra A, Giles GR. Quadruple chemotherapy for advanced colorectal cancer. Clinical Oncology 1983;9(2):185‐186.
Cunningham {published and unpublished data}
    1. Cunningham D, Pyrhonen S, Janes RD, Punt CJA, Hickish T, Heikkila T, Johannesen T, Starkhammer H, Topham CA, Ong E, Herait P, Jacques C. A phase III multicenter randomized study of CPT‐11 versus supportive care alone in patients with 5FU‐resistant metastatic colorectal cancer. Proceedings ASCO 1998.
    1. Cunningham, D, Pyrhonen, S, James, R. D, Punt, C. J. A, Hickish, T. F, Heikkila, R, Johannesen, T. B, Starkhammer, H, Topham, C. A, Awad, L, Jacques, C, Herait. P. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352(9138):1413‐8. - PubMed
Gerard {published data only}
    1. Gerard A, Buyse M, Pector JC, Bleiberg H, Arnaud J P, Willems G, Delvaux G, Lise M, Nitti D, Depadt G, et al. Hepatic artery ligation with and without portal infusion of 5‐FU. A randomized study in patients with unresectable liver metastases from colorectal carcinoma. The E.O.R.T.C. Gastrointestinal Cancer Cooperative Group (G.I. Group).. Eur‐J‐Surg‐Oncol 1991 Jun;17(3):289‐94. - PubMed
Glimelius {published and unpublished data}
    1. Glimelius B, Hoffman K, Graf W, Haglund U, Nyren O, Pahlman L, Sjoden P O. Cost‐effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann‐Oncol 1995 Mar;6(3):267‐74. - PubMed
Hafstrom {published and unpublished data}
    1. Hafstrom L, Engras B, Holmberg SB, Gustavsson B, Jonsson P, Linder P, Naredi P, Tidebrant. Treatment of liver metastases from colorectal cancer with hepatic artery occlusion, intraportal 5‐fluouracil infusion, and oral allopurinol. Cancer 1994;74(10):2749‐2756. - PubMed
Hunt {published and unpublished data}
    1. Hunt TM, Flowerdew A D, Birch S J, Williams J D, Mullee M A, Taylor I. Prospective randomized controlled trial of hepatic arterial embolization or infusion chemotherapy with 5‐fluorouracil and degradable starch microspheres for colorectal liver metastases. Br‐J‐Surg 1990 Jul;77(7):779‐82. - PubMed
Nordic {published and unpublished data}
    1. Glimelius B, Graf W, Hoffman K, Pahlman L, Sjoden PO, Wennberg A. General condition of asymptomatic patients with advanced colorectal cancer receiving palliative chemotherapy. A longitudinal study. Acta‐Oncol 1992;31(6):645‐51. - PubMed
    1. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J‐Clin‐Oncol 1992 Jun;10(6):904‐11. - PubMed
Rougier {published and unpublished data}
    1. Rougier P, Hay J M, Ollivier J M, Escat J, Laplanche A, Elias D, Lasser P, Huguier M. A controlled multicenter trial of intrahepatic chemotherapy (IHC) vs standard palliative treatment for colorectal liver metastases. Proceesings ASCO 1990;9:A403.
    1. Rougier P, Laplanche A, Huguier M, Hay J M, Ollivier J M, Escat J, Salmon R, Julien M, Roullet Audy J C, Gallot D. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long‐term results of a prospective randomized trial. J‐Clin‐Oncol 1992;10(7):1112‐8. - PubMed
Scheithauer {published data only}
    1. Scheithauer W, Depisch D, Schiessel R, Rosen H, Sebesta C, Ludwig H. Influence of chemotherapy on survival and quality of life (QOL) in patients with metastatic colorectal cancer (CC): a randomized study. Proceedings ASCO 1990;9:a1176.
    1. Scheithauer W, Rosen H, Kornek G V, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993;306(6880):752‐5. - PMC - PubMed
Smyth {published and unpublished data}
    1. Smyth JF, Hardcastle J D, Denton G, Alderson D, Grace R H, Mansi J L, Yosef H M, Nordle O, Lauri H, Wahlby S. Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer. Ann‐Oncol 1995 Nov;6(9):948‐9. - PubMed
Yorkshire {published data only}
    1. Yorkshire Gastrointestinal Tumour Group. Chemotherapy after palliative resection of colorectal cancer. Br‐J‐Surg 1984 Apr;71(4):283‐6. - PubMed

Additional references

ACCMAP 1992
    1. Advanced Colorectal Cancer Meta‐analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer : evidence in terms of response rate. J Clin Oncol 1992;10(6):896‐903. - PubMed
ACCMAP 1994
    1. Advanced Colorectal Cancer Meta‐analysis Project. Meta‐analysis of randomized trials testing the biochemical modulation of 5‐fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994;12:960‐9. - PubMed
Blijham 1997
    1. Blijham G, Schmitt C, Aussage P, HenryLaunois B, Jolain B, Herait P. Cost‐effectiveness of Irinotecan (CPT‐11) and best estimated chemotherapy regimen in patients with metastatic colorectal cancer after failure of 5fluorouracil (5FU) containing regimen: Results based on a phase III trial. Eur‐J‐Cancer 1997;33(S9):OP4.
Cunningham 1993
    1. Cunningham D, Findlay M. The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 1993;29A(15):2077‐9. - PubMed
De Gramont 1997
    1. Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low‐dose leucovorin and fluorouracil bolus with bimonthly high‐dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J‐Clin‐Oncol 1997;15(2):808‐15. - PubMed
Delfino 1996
    1. Delfino C, Bosch B, Caccia G. Cost effectiveness of palliative care for advanced colorectal carcinoma. Proceedings ASCO 1996;A 942.
Gerard 1992
    1. Gerard K. Cost‐utility in practice: a policy maker's guide to the state of the art. Health Policy 1992;21:249‐79. - PubMed
Groener 1997
    1. Groener M G, Ineveld B M, Byttebier G. Evaluation of relative costs of the cytostatic agents Tomudex and 5‐Fluorouracil plus Leucovorin as treatments for advanced colorectal cancer. Eur‐J‐Cancer 1997;33(S9):OP11.
Hale 1997
    1. Hale J, Cohen D, Maughan T. Economics of the MRC Colorectal Working Party CR06 Trial. Eur J Cancer 1997;33(S9):OP13.
Jadad 1996
    1. Jadad AR, Moore R A, Carroll D, Jenkinson C, Reynolds D J, Gavaghan D J, McQuay H J. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control‐Clin‐Trials 1996 Feb;17(1):1‐12. - PubMed
Jefferson 1996
    1. Jefferson TO, Demicheli V, Mugford M. Elementary Economic Evaluation in Health Care. Blackwell BMJ Books May 2000:BMJ Books 1996.
Jefferson 1998
    1. Jefferson TO, Demicheli M. Methodological quality of economic modelling studies: a case study with hepatitis B vaccines. Pharmacoeconomics 1998;14:251‐7. - PubMed
Kerr 1997
    1. Kerr D J, O'Connor K M. The costs of managing advanced colorectal cancer: a broad perspective. Anticancer‐Drugs 1997;Suppl 2:S23‐6. - PubMed
Lokich 1989
    1. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid‐Atlantic Oncology Program Study. J Clin Oncol 1989;7(4):425‐32. - PubMed
Lokich 1996
    1. Lokich J J, Moore C L, Anderson N R. Comparison of costs for infusion versus bolus chemotherapy administration: Analysis of five standard chemotherapy regimens in three common tumors .1. Model projections for cost based on charges. Cancer 1996;78(2):294‐299. - PubMed
MA Group 1996
    1. Meta‐analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Journal of National Cancer Institute 1996;252‐8. - PubMed
ONS 1997
    1. Office for National Statistics. Mortality Statistics: cause, England and Wales 1997. London: HMSO.
ONS 1998
    1. Office for National Statistics. Cancer Statistics Registrations : England and Wales, 1992. London. HMSO, 1998.
Redmond 1998
    1. Redmond K. Assessing patients' needs and preferences in the management of advanced colorectal cancer. Br J Cancer 1998;77(Suppl. 2):5‐7. - PMC - PubMed
Ross 1996
    1. Ross P, Heron J, Cunningham D. Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Eur‐J‐Cancer 1996;32A Suppl 5:S13‐7. - PubMed
Seymour 1997
    1. Seymour MT, Stenning SP, Cassidy J. Attitudes and practice in the management of metastatic colorectal cancer in Britain. Colorectal Cancer Working Party of the UK Medical Research Council. Clin‐Oncol‐R‐Coll‐Radiol 1997;9(4):248‐51. - PubMed
Udvarhelyi 1992
    1. Udvarhelyi S, Colditz GA, Rai A, Epstein AM. Cost‐effectiveness and cost‐benefit analyses in the medical literature. Are methods being used correctly?. Annals of Internal Medicine 1992;116:238‐44. - PubMed
Weiss 1986
    1. Weiss L, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder Mea. Hematogenous metastatic patterns in colonic carcinoma : an analysis of 1541 necropsies. J Pathol 1986;150:195‐203. - PubMed
Wils 1998
    1. Wils J, Sahmoud T, Sobrero A, et al. Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG. Tumori 1998;84(3):335‐47. - PubMed

Publication types

Substances